After a Massachusetts drug company paused its phase 1 study of a leukemia drug candidate in June following a study participant's death, the FDA put a clinical hold on the trial Aug. 11. 

HHS halted all research that involved human subjects at a New York City psychiatric hospital as the agency investigates a drug trial participant's suicide, The New York Times reported Aug. 10. 

Two decades after working in the kitchen at Martha's Vineyard Hospital, Valci Carvalho became the hospital's pharmacy director, The Vineyard Gazette reported Aug. 10. 

The list prices of the 25 most popular Medicare Part D drugs, on average, have more than tripled since they first entered the market, the AARP said Aug. 10. 

Denmark-based Novo Nordisk plans to acquire Inversago Pharma for up to $1.8 billion dollars, depending on whether the clinical-stage obesity drugmaker meets certain development and sales milestones. 

This live episode from the Becker’s Hospital Review 13th Annual Meeting in Chicago features Desi Kotis, Chief Pharmacy Executive at University of San Francisco Health System. Here, she discusses the opportunities that are coming up now that the federal state…

340B Health welcomed two hospital leaders — one pharmacy director and one chief medical officer — to its board of directors. 

The number of ongoing drug shortages is nearing an all-time high, causing most U.S. hospitals to inject 5 percent to 20 percent more funds into their pharmacy budgets. 

After three months of Novo Nordisk restricting supply to lower doses of its popular weight loss drug Wegovy, the company said Aug. 10 it will continue to limit its supply. 

The Defense Department has entered into an agreement with Valisure, an independent laboratory company, to advance a pharmaceutical quality risk assessment pilot study of generic drugs, according to an Aug. 8 news release.